Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab.
Τίτλος | Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. |
Publication Type | Journal Article |
Year of Publication | 2019 |
Authors | Economopoulou, P., Kotoula V., Koliou G-A., Papadopoulou K., Christodoulou C., Pentheroudakis G., Lazaridis G., Arapantoni-Dadioti P., Koutras A., Bafaloukos D., Papakostas P., Patsea H., Pavlakis K., Pectasides D., Kotsakis A., Razis E., Aravantinos G., Samantas E., Kalogeras K. T., Economopoulos T., Psyrri A., & Fountzilas G. |
Journal | Transl Oncol |
Volume | 12 |
Issue | 5 |
Pagination | 739-748 |
Date Published | 2019 May |
ISSN | 1936-5233 |
Abstract | BACKGROUND: Src, CDKN1B, and JAK2 play a crucial role in the coordination of cell signaling pathways. In the present study, we aim to investigate the prognostic significance of these biomarkers in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab (T). |
DOI | 10.1016/j.tranon.2019.02.010 |
Alternate Journal | Transl Oncol |
PubMed ID | 30877976 |
PubMed Central ID | PMC6423363 |